1. Home
  2. AC vs LQDA Comparison

AC vs LQDA Comparison

Compare AC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AC
  • LQDA
  • Stock Information
  • Founded
  • AC 1976
  • LQDA 2004
  • Country
  • AC United States
  • LQDA United States
  • Employees
  • AC N/A
  • LQDA N/A
  • Industry
  • AC Investment Bankers/Brokers/Service
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • AC Finance
  • LQDA Health Care
  • Exchange
  • AC Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • AC 779.1M
  • LQDA 856.5M
  • IPO Year
  • AC N/A
  • LQDA 2018
  • Fundamental
  • Price
  • AC $36.43
  • LQDA $10.65
  • Analyst Decision
  • AC
  • LQDA Strong Buy
  • Analyst Count
  • AC 0
  • LQDA 8
  • Target Price
  • AC N/A
  • LQDA $27.14
  • AVG Volume (30 Days)
  • AC 5.8K
  • LQDA 773.7K
  • Earning Date
  • AC 11-08-2024
  • LQDA 11-13-2024
  • Dividend Yield
  • AC 0.55%
  • LQDA N/A
  • EPS Growth
  • AC 65.12
  • LQDA N/A
  • EPS
  • AC 2.62
  • LQDA N/A
  • Revenue
  • AC $13,657,000.00
  • LQDA $15,610,000.00
  • Revenue This Year
  • AC N/A
  • LQDA N/A
  • Revenue Next Year
  • AC N/A
  • LQDA $227.73
  • P/E Ratio
  • AC $13.88
  • LQDA N/A
  • Revenue Growth
  • AC N/A
  • LQDA N/A
  • 52 Week Low
  • AC $28.58
  • LQDA $6.69
  • 52 Week High
  • AC $43.85
  • LQDA $16.99
  • Technical
  • Relative Strength Index (RSI)
  • AC 50.54
  • LQDA 52.84
  • Support Level
  • AC $35.05
  • LQDA $9.93
  • Resistance Level
  • AC $37.35
  • LQDA $10.95
  • Average True Range (ATR)
  • AC 1.01
  • LQDA 0.45
  • MACD
  • AC -0.02
  • LQDA -0.02
  • Stochastic Oscillator
  • AC 40.00
  • LQDA 67.14

About AC Associated Capital Group Inc.

Associated Capital Group Inc is a diversified global financial services company. It operates in the business of alternative investment management, institutional research services, and cash and other assets through subsidiaries. The activities of its subsidiaries comprise publishing daily research notes and full reports using private market value with a catalyst methodology and also products and customized solutions utilizing private market value with catalyst method of investing.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: